Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
6.56% $2.36
America/New_York / 28 mar 2024 @ 15:38
FUNDAMENTALS | |
---|---|
MarketCap: | 160.54 mill |
EPS: | -1.750 |
P/E: | -1.350 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 68.17 mill |
Avg Daily Volume: | 0.291 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.350 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.23x |
Company: PE -1.350 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0640 (-102.72%) $-2.42 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 2.17 - 2.54 ( +/- 7.69%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Jorgensen Nathan D. | Sell | 6 310 | Common Stock |
2024-03-01 | Chakraborty Tirtha | Sell | 5 576 | Common Stock |
2024-03-01 | Ang Robert | Sell | 12 657 | Common Stock |
2024-02-06 | Attar Eyal C. | Sell | 1 180 | Common Stock |
2024-02-06 | Ang Robert | Sell | 2 788 | Common Stock |
INSIDER POWER |
---|
97.70 |
Last 99 transactions |
Buy: 33 478 720 | Sell: 91 989 993 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.36 (6.56% ) |
Volume | 0.363 mill |
Avg. Vol. | 0.291 mill |
% of Avg. Vol | 124.93 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.